Review of Patents and Commercial Opportunities Involving Mesenchymal Stromal Cells (MSCs) Therapies in Osteoarthritis
Sowmya Viswanathan and Alejandro Gomez-Aristizabal
Affiliation: Cell Therapy Program, University Health Network, Princess Margaret Hospital, 620 University Avenue, Suite 8-105, Toronto, ON M5G 2C1, Canada.
Keywords: Cartilage, clinical trials, companies, immunoregulation, mesenchymal stromal cells, osteoarthritis, therapies.
Osteoarthritis (OA) is a degenerative joint disease that affects cartilage, subchondral bone, the synovium and
synovial fluid and has limited treatment options. With an ageing population and growing health economic costs, novel
treatment options for OA are urgently needed. Mesenchymal stromal cells (MSCs) with their demonstrated abilities to
modulate pain and inflammation, and with their ability to contribute to chondrocyte differentiation and proliferation are
therefore being investigated globally for their potential to provide novel treatment options for OA patients. In this paper,
we review the preclinical studies and early clinical trials, and the patent landscape for the use of MSCs for the treatment of
Rights & PermissionsPrintExport